Targeted Therapy in Translational Cancer Research

Description

Targeted Therapy in Translational Cancer Research for the Translational Oncology series provides a comprehensive overview of recent developments in our understanding of tumor biology, elucidates the roles of targets and pathways involved in carcinogenesis, and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy.

• Introduces cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer
• Covers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine
• Summarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities

Contents

List of Contributors, vii
Series Foreword, xiii
Foreword, xv
Preface, xvii

Part I Principles of Targeted Therapies
1 Toward Personalized Therapy for Cancer, 3
Ashley M. Holder and FundaMeric-Bernstam
2 Combining Targeted Therapies, 14
Jordi Rodon, Analia Azaro, Davis Torrejon, and Razelle Kurzrock
3 Principles of Targeted Immunotherapy, 27
Susanne H. C. Baumeister and Glenn Dranoff
4 Cancer Stem Cell Principles, 39
Allison C. Sharrow, Gabriel Ghiaur, and Richard J. Jones
5 The Tumor Microenvironment as a Target for Therapeutic Intervention, 47
Hua Fang and Yves A. DeClerck
6 The Role of Angiogenesis in Cancer, 64
Morgan Taylor, Robert L. Coleman, and Anil K. Sood
7 Epigenetics and Epigenetic Therapy of Cancer, 72
Omotayo Fasan, Patrick Boland, PatriciaKropf, and Jean-Pierre J. Issa
8 The Role of microRNAs in Cancer, 80
Gianpiero Di Leva and Carlo M. Croce
9 AcuteMyeloidLeukemia, 89
Ofir Wolach and Richard M. Stone
10 Targeted and Functional Imaging, 101
Jian Q. (Michael) Yu, Drew A. Torigian, and Abass Alavi

Part II Targeted Therapy in Hematological Malignancies
11 Targeted Therapies in Chronic Myeloid Leukemia, 113
Elias Jabbour and Jorge Cortes
12 Targeted Therapy for Acute Lymphoblastic Leukemia, 121
Nitin Jain, Susan O’Brien, and Farhad Ravandi-Kashani
13 Chronic Lymphocytic Leukemia, 130
Preetesh Jain and Susan O’Brien
14 Multiple Myeloma, 145
Giada Bianchi and Kenneth C. Anderson
15 The Impact of Genomics on Targeted Therapy in Multiple Myeloma and Lymphomas, 157
Jens G. Lohr and Birgit Knoechel
16 Targeted Therapy in Myelodysplastic Syndromes, 162
Guillermo Montalb´an-Bravo and Guillermo Garc´ýa-Manero
17 Lymphoma and Targeted Therapies, 169
Sonali M. Smith and Julie M. Vose
Part III Targeted Therapy in Solid Tumors
18 Targeted Therapy in Solid Tumors: Brain, 179
Shiao-PeiWeathers, Barbara J. O’Brien, John F. de Groot, andW. K. Alfred Yung
19 Targeted Therapy for Breast Cancer, 190
Harold J. Burstein
20 Targeted Therapy in Solid Tumors: Colorectal Cancer, 193
Maen Abdelrahim, Scott Kopetz, and David Menter
21 Endometrial Cancer, 205
Jessica L. Bowser, Russell R. Broaddus, Robert L. Coleman, and Shannon N. Westin
22 Targeted Therapy in Solid Tumors: Head and Neck, 216
Marcus M. Monroe and Jeffrey N. Myers
23 Targeted Therapy in Solid Tumors: Lung Cancer, 224
Saiama N.Waqar, Daniel Morgensztern, and Roy S. Herbst
24 Targeted Therapy in Melanoma, 231
Keith T. Flaherty
25 Ovarian Cancer, 240
Shannon N.Westin, Larissa A. Meyer, and Robert L. Coleman
26 Molecular Therapeutics: Pancreatic Cancer, 255
David Fogelman, Milind Javle, and James Abbruzzese
27 Targeted Therapies for Pediatric Solid Tumors, 263
Jasmine Quynh Dao and Patrick A. Zweidler-McKay
28 Prostate Cancer, 273
William G. Nelson, Michael C. Haffner, and Srinivasan Yegnasubramanian
29 Renal Cell Carcinoma and Targeted Therapy, 287
Benjamin A. Gartrell, Alexander C. Small, William K. Oh, and Matthew D. Galsky
30 Targeted Therapy in Solid Tumors: Sarcomas, 296
Anthony P. Conley, Vinod Ravi, and Shreyaskumar Patel

Part IV Targeted Therapy for Specific Molecular Aberrations
31 RAS-RAF-MEK Pathway: Aberrations and Therapeutic Possibilities, 305
Javier Munoz and Filip Janku
32 The Phosphatidylinositol 3-Kinase Pathway in Human Malignancies, 315
Samuel J. Klempner,Thanh-Trang Vo, Andrea P. Myers, and Lewis C. Cantley
33 Current Status and Future Direction of PARP Inhibition in Cancer Therapy, 325
Saeed Rafii, Stan Kaye and Susana Banerjee
34 Targeting the c-Met Kinase, 341
Chad Tang, M. Angelica Cortez, David Hong, and James W. Welsh
35 KIT Kinase, 347
Scott E. Woodman
36 TP53, 353
Kensuke Kojima and Michael Andreeff

Part V Future Perspectives
37 Future Perspectives, 363
Rabih Said and Apostolia-Maria Tsimberidou

Index, 371

Authors

Apostolia-Maria Tsimberidou, MD PhD
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, TX, USA

Razelle Kurzrock
Center for Personalized Cancer Therapy, UC San Diego - Moores Cancer Center
La Jolla, CA, USA

Kenneth C. Anderson MD
LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School
Boston, MA, USA